Kymera · pitchdeck
Kymera | Investor Presentation Deck | 60 slides
60 pages · 4 arc beats · 3 loops
Kymera | Investor Presentation Deck | 60 slides
Kymera · 2023-08 arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
124681012141618202224262830323436384042444648505254565860
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 30 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Attention 3 slides 100% 3/3 slides 100% 3/3 slides · 10 hits — 0/3 slides
33.3% 1/3 slides — 0/3 slides
100% 3/3 slides — 0/3 slides
Interest 5 slides 100% 5/5 slides 100% 5/5 slides · 22 hits — 0/5 slides
80% 4/5 slides · 6 hits 60% 3/5 slides 100% 5/5 slides 100% 5/5 slides Desire 20 slides 100% 20/20 slides 100% 20/20 slides · 97 hits — 0/20 slides
50% 10/20 slides 15% 3/20 slides 100% 20/20 slides 20% 4/20 slides Action 2 slides 100% 2/2 slides 100% 2/2 slides · 10 hits — 0/2 slides
— 0/2 slides
— 0/2 slides
100% 2/2 slides — 0/2 slides
Slide inventory
60 every slide · same image gating as the playbook
03
The slide uses a split-layout with company identity on the left and a list of achievements on the right.summarize
Open slide detailBeat · Attention
04
TPD = Targeted Protein Degradation. The slide uses a four-column layout to structure the company's value proposition.present_solution
05
TPD stands for Targeted Protein Degradation.show_traction
06
The slide uses a dot-matrix representation to indicate therapeutic focus areas for specific drug candidates.present_solution
07
The slide uses a Gantt-chart style layout to show the progression of various drug programs.plan_implementation
09
This is a stylistic section divider slide with an abstract background.transition
Open slide detailBeat · Desire
10
The slide uses a biological pathway diagram to illustrate the mechanism of action and a callout box for the therapeutic thesis.present_solution
Open slide detailBeat · Desire
11
The slide uses a combination of a biological mechanism diagram, a market data table, and a callout box for competitive limitations.size_opportunity
Open slide detailBeat · Desire
12
The slide uses a side-by-side comparison framework to contrast healthy volunteer data with patient data.analyze_data
Open slide detailBeat · Desire
13
The slide uses a bulleted list structure to categorize findings between healthy volunteers and patients, concluding with a strategic partnership milestone.show_traction
Open slide detailBeat · Desire
15
The slide provides a breakdown of patient outcomes including completion and withdrawal reasons.analyze_data
Open slide detailBeat · Desire
16
HS = Hidradenitis Suppurativa, AD = Atopic Dermatitis, HV = Healthy Volunteers, PK = Pharmacokinetics, PD = Pharmacodynamics, MS = Mass Spectrometry, LLOQ = Lowanalyze_data
Open slide detailBeat · Desire
17
The chart demonstrates therapeutic efficacy by showing post-treatment levels (Day 28) dropping below or equal to the healthy subject baseline.show_traction
Open slide detailBeat · Desire
18
The slide compares cytokine inhibition across three cohorts (MAD3 Healthy Subjects, Part C AD Patients, Part C HS Patients) using two different stimuli (LPS andshow_traction
Open slide detailBeat · Desire
19
The chart specifically visualizes IL-6 reduction over time, while the table summarizes max reduction across four markers.show_traction
Open slide detailBeat · Desire
20
The slide displays 12 individual bar charts (4 for AD, 8 for HS) representing gene expression changes.analyze_data
Open slide detailBeat · Desire
21
Data based on N=7 patients. Includes error bars representing standard error or confidence intervals.show_traction
22
The chart tracks patient outcomes over time, showing a shift from severe/moderate to mild categories.show_traction
23
Includes before/after photography, clinical efficacy table, and biomarker reduction charts.illustrate_case
24
The slide uses a comparison table to highlight efficacy metrics (EASI, Pruritus NRS) across different time points and benchmarks.show_traction
25
Data presented for All HS Patients (N=12) and Moderate to Severe (N=10) subgroups.analyze_data
Open slide detailBeat · Desire
26
Data presented across three line charts comparing 'All HS Patients' vs 'Moderate to Severe' subgroups.show_traction
Open slide detailBeat · Desire
27
The charts demonstrate a shift from higher severity scores (orange/red) to lower severity scores (blue/black) over time.show_traction
Open slide detailBeat · Desire
28
Includes patient profile, clinical efficacy table, before/after photos, and a bar chart of biomarker reduction.illustrate_case
Open slide detailBeat · Desire
29
Includes before/after clinical photos and a longitudinal biomarker chart.illustrate_case
30
The slide uses a comparison table to highlight superior efficacy metrics for the drug candidate.compare_peers
31
The footer highlights the safety profile: no serious adverse events (SAEs), no drug-related infections, and no dose interruptions or discontinuations.analyze_data
32
Data presented as mean change from baseline with 90% CI. Includes table of mean values for delta QTc and absolute QTc.analyze_data
35
The slide uses a complex biological pathway diagram to illustrate the mechanism of action and the problem of redundant signaling pathways.frame_problem
36
The slide presents two charts: a tumor growth inhibition curve and a PK/PD correlation chart showing drug concentration vs. target degradation over time.show_traction
37
The slide outlines a standard oncology dose-escalation study design (3+3 or similar) followed by expansion cohorts.plan_implementation
38
The slide presents clinical trial data for a drug candidate, comparing PK profiles across four dose levels (DL1-DL4).analyze_data
39
The slide presents longitudinal pharmacodynamic (PD) data for three targets across four dose levels, comparing clinical results to preclinical expectations.show_traction
40
The slide uses a split-layout to contrast clinical data findings with the strategic clinical development plan.show_traction
42
Includes a table of prevalence/incidence data and a biological pathway diagram.size_opportunity
Open slide detailLoop · Golden Circle
43
The slide presents two charts: a tumor volume growth curve over time and a PK/PD profile showing drug concentration and target knockdown over 240 hours.show_traction
Open slide detailLoop · Golden Circle
44
The slide outlines a standard oncology clinical trial design (3+3 or similar dose escalation) followed by cohort expansion.plan_implementation
Open slide detailLoop · Golden Circle
46
Includes a line chart for PK profiles and a table for PK parameters (Cmax, AUClast, Vd, CL, t1/2).analyze_data
Open slide detailLoop · Golden Circle
47
Includes a line chart showing % change over time and a summary table of patient-level degradation data.show_traction
Open slide detailLoop · Golden Circle
48
Includes bar charts for SAA/CRP, a longitudinal line chart for SOCS3, and a scatter plot showing correlation.show_traction
Open slide detailLoop · Golden Circle
49
Data cut-off date May 1, 2023. DL1-3 completed, DL4 open.show_traction
Open slide detailLoop · Golden Circle
51
Includes a DepMap CRISPR sensitivity chart and a biological process diagram showing the MDM2-p53 feedback loop.present_solution
52
The slide uses a biological pathway diagram to illustrate the mechanism of action and Western blot data to validate the claim.present_solution
53
Includes a table comparing clinical stage and potency metrics (IC50, DC50) across multiple competitors.compare_peers
54
Data presented as tumor volume growth curves and Kaplan-Meier survival plots.show_traction
55
The slide uses a series of bar charts to demonstrate the mechanism of action of the drug candidate KT-253 compared to vehicle and DS-3032.present_solution
56
Shows two distinct experiments: DFAM-68555 (leukemia burden) and MOLM-13 (tumor volume).show_traction
57
The slide title mentions KT-333, but the content refers to KT-253 throughout; this is likely a typo in the source slide.plan_implementation
58
The slide uses a split-layout to contrast mechanism benefits (left) with strategic market opportunity (right).present_solution
60
The slide serves as a standard closing/contact slide, featuring a high-impact photo of the company team at Nasdaq.state_next_steps
Open slide detailBeat · Action